M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS
Shinkichi Takamori, Naoki Haratake, Kentaro Nonaka, Mai Moriya, Atrayee Bhattacharya, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Mark D. Long, Donald W. Kufe
This study shows M1C is necessary for daraxonrasib resistance in NSCLC KRAS(G12C) mutant cells and identifies M1C as a potential therapeutic target.
bioRxiv · Jun 23, 2026 · PreprintCancer Biology